Bolt Biotherapeutics (BOLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bolt Biotherapeutics (BOLT) has a cash flow conversion efficiency ratio of -0.270x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.16 Million) by net assets ($26.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BOLT stock market capitalisation for the company's overall valuation and market capitalisation.
Bolt Biotherapeutics - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Bolt Biotherapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bolt Biotherapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bolt Biotherapeutics ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Bolt Biotherapeutics to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Future Market Networks Limited
NSE:FMNL
|
0.072x |
|
Compass Group PLC
LSE:CPG
|
0.258x |
|
STRATHMORE PLUS URANIUM
F:TO3
|
-0.068x |
|
Electroarges S
RO:ELGS
|
-0.001x |
|
XP Power Ltd
LSE:XPP
|
0.035x |
|
BlackRock Greater Europe Investment Trust plc
LSE:BRGE
|
-0.008x |
|
Coil S.A./N.V
PA:ALCOI
|
0.006x |
|
Lanakam S.A
AT:LANAC
|
0.007x |
Annual Cash Flow Conversion Efficiency for Bolt Biotherapeutics (2018–2025)
The table below shows the annual cash flow conversion efficiency of Bolt Biotherapeutics from 2018 to 2025. View BOLT share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.50 Million | $-39.85 Million | -1.503x | -40.31% |
| 2024-12-31 | $57.20 Million | $-61.29 Million | -1.072x | -73.76% |
| 2023-12-31 | $112.74 Million | $-69.53 Million | -0.617x | -38.25% |
| 2022-12-31 | $171.51 Million | $-76.50 Million | -0.446x | -95.51% |
| 2021-12-31 | $250.12 Million | $-57.07 Million | -0.228x | -150.61% |
| 2020-12-31 | $-104.95 Million | $-47.31 Million | 0.451x | -21.55% |
| 2019-12-31 | $-45.85 Million | $-26.34 Million | 0.575x | -7.20% |
| 2018-12-31 | $-15.94 Million | $-9.87 Million | 0.619x | -- |
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agon… Read more